(VIANEWS) – Anterix (ATEX), The Blackstone Group (BX), Kinross Gold (KGC) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Anterix (ATEX)
48.9% sales growth and 9.55% return on equity
Anterix Inc. operates as a wireless communications company. The company focuses on commercializing its spectrum assets to enable the targeted utility and critical infrastructure customers to deploy private broadband networks, technologies, and solutions. It holds licensed spectrum in the 900 MHz band with nationwide coverage throughout the United States, Alaska, Hawaii, and Puerto Rico. The company was formerly known as pdvWireless, Inc. and changed its name to Anterix Inc. in August 2019. Anterix Inc. was incorporated in 1997 and is headquartered in Woodland Park, New Jersey.
Earnings Per Share
As for profitability, Anterix has a trailing twelve months EPS of $0.83.
PE Ratio
Anterix has a trailing twelve months price to earnings ratio of 38.99. Meaning, the purchaser of the share is investing $38.99 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.55%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is a negative 150% and a negative 263.6%, respectively.
Sales Growth
Anterix’s sales growth is 199.3% for the present quarter and 48.9% for the next.
Volume
Today’s last reported volume for Anterix is 132804 which is 40.56% above its average volume of 94482.
Revenue Growth
Year-on-year quarterly revenue growth grew by 119.9%, now sitting on 3.54M for the twelve trailing months.
2. The Blackstone Group (BX)
18.4% sales growth and 20.59% return on equity
Blackstone Inc. is an alternative asset management firm specializing in real estate, private equity, hedge fund solutions, credit, secondary funds of funds, public debt and equity and multi-asset class strategies. The firm typically invests in early-stage companies. It also provide capital markets services. The real estate segment specializes in opportunistic, core+ investments as well as debt investment opportunities collateralized by commercial real estate, and stabilized income-oriented commercial real estate across North America, Europe and Asia. The firm's corporate private equity business pursues transactions throughout the world across a variety of transaction types, including large buyouts,special situations, distressed mortgage loans, mid-cap buyouts, buy and build platforms, which involves multiple acquisitions behind a single management team and platform, and growth equity/development projects involving significant majority stakes in portfolio companies and minority investments in operating companies, shipping, real estate, corporate or consumer loans, and alternative energy greenfield development projects in energy and power, property, dislocated markets, shipping opportunities, financial institution breakups, re-insurance, and improving freight mobility, financial services, healthcare, life sciences, infrastructure, enterprise tech and consumer, as well as consumer technologies. The firm considers investment in Asia and Latin America. It seeks to invest between $0.25 million and $900 million per transaction. It invests in companies with enterprise value between $500 million and $5000 million. It has a three year investment period. Its hedge fund business manages a broad range of commingled and customized fund solutions and its credit business focuses on loans, and securities of non-investment grade companies spread across the capital structure including senior debt, subordinated debt, preferred stock and common equity. Blackstone Inc. was founded in 1985 and is headquartered in New York, New York with additional offices across Asia, Europe, North America and Central America.
Earnings Per Share
As for profitability, The Blackstone Group has a trailing twelve months EPS of $1.84.
PE Ratio
The Blackstone Group has a trailing twelve months price to earnings ratio of 67.1. Meaning, the purchaser of the share is investing $67.1 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.59%.
Sales Growth
The Blackstone Group’s sales growth is 13.9% for the current quarter and 18.4% for the next.
Moving Average
The Blackstone Group’s worth is higher than its 50-day moving average of $123.25 and higher than its 200-day moving average of $116.96.
3. Kinross Gold (KGC)
16% sales growth and 7.06% return on equity
Kinross Gold Corporation, together with its subsidiaries, engages in the acquisition, exploration, and development of gold properties principally in the United States, Brazil, Chile, Canada, and Mauritania. The company operates the Fort Knox mine and the Manh Choh project in Alaska, as well as the Round Mountain and the Bald Mountain mines in Nevada, the United States; the Paracatu mine in Brazil; the La Coipa and the Lobo-Marte project in Chile; the Tasiast mine in Mauritania; and the Great Bear project in Canada. It is also involved in the extraction and processing of gold-containing ores; reclamation of gold mining properties; and production and sale of silver. Kinross Gold Corporation was founded in 1993 and is headquartered in Toronto, Canada.
Earnings Per Share
As for profitability, Kinross Gold has a trailing twelve months EPS of $0.34.
PE Ratio
Kinross Gold has a trailing twelve months price to earnings ratio of 18.75. Meaning, the purchaser of the share is investing $18.75 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.06%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter is a negative 28.6% and positive 16.7% for the next.
4. QUALCOMM (QCOM)
12.7% sales growth and 38.27% return on equity
QUALCOMM Incorporated engages in the development and commercialization of foundational technologies for the wireless industry worldwide. It operates through three segments: Qualcomm CDMA Technologies (QCT); Qualcomm Technology Licensing (QTL); and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on 3G/4G/5G and other technologies for use in wireless voice and data communications, networking, computing, multimedia, and position location products. The QTL segment grants licenses or provides rights to use portions of its intellectual property portfolio, which include various patent rights useful in the manufacture and sale of wireless products comprising products implementing CDMA2000, WCDMA, LTE and/or OFDMA-based 5G standards and their derivatives. The QSI segment invests in early-stage companies in various industries, including 5G, artificial intelligence, automotive, consumer, enterprise, cloud, IoT, and extended reality, and investments, including non-marketable equity securities and, to a lesser extent, marketable equity securities, and convertible debt instruments. It also provides development, and other services and related products to the United States government agencies and their contractors. The company was incorporated in 1985 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, QUALCOMM has a trailing twelve months EPS of $7.01.
PE Ratio
QUALCOMM has a trailing twelve months price to earnings ratio of 24.44. Meaning, the purchaser of the share is investing $24.44 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 38.27%.
Previous days news about QUALCOMM(QCOM)
- The zacks analyst blog highlights NVIDIA, Micron Technology, advanced micro devices and QUALCOMM. According to Zacks on Tuesday, 11 June, "Stocks recently featured in the blog include: NVIDIA Corp. (NVDA Quick QuoteNVDA – Free Report) , Micron Technology, Inc. (MU Quick QuoteMU – Free Report) , Advanced Micro Devices (AMD Quick QuoteAMD – Free Report) and QUALCOMM Inc. (QCOM Quick QuoteQCOM – Free Report) .", "Given the promising future, it would be wise to invest in semiconductor stocks like NVIDIA Corp., Micron Technology, Inc., Advanced Micro Devices and QUALCOMM Inc., which investors can gain from in the near term."
5. Option Care Health (OPCH)
9.9% sales growth and 19.62% return on equity
Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including Crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders. It also offers treatments to manage the progression of neurological disorders, such as multiple sclerosis, duchenne muscular dystrophy, and others; infusion therapies for bleeding disorders; therapies that women need to survive and thrive through high-risk pregnancies; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications, as well as nursing services. Option Care Health, Inc. is headquartered in Bannockburn, Illinois.
Earnings Per Share
As for profitability, Option Care Health has a trailing twelve months EPS of $1.53.
PE Ratio
Option Care Health has a trailing twelve months price to earnings ratio of 18.45. Meaning, the purchaser of the share is investing $18.45 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.62%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 12.8%, now sitting on 4.43B for the twelve trailing months.
Sales Growth
Option Care Health’s sales growth is 9.5% for the current quarter and 9.9% for the next.
Moving Average
Option Care Health’s value is under its 50-day moving average of $30.25 and way below its 200-day moving average of $31.56.
Volume
Today’s last reported volume for Option Care Health is 272051 which is 78.58% below its average volume of 1270460.
Previous days news about Option Care Health(OPCH)
- Zacks.com featured highlights include j.jill, option care health and amphenol. According to Zacks on Tuesday, 11 June, "Jill (JILL Quick QuoteJILL – Free Report) , Option Care Health (OPCH Quick QuoteOPCH – Free Report) and Amphenol (APH Quick QuoteAPH – Free Report) ."
6. STAAR Surgical Company (STAA)
8.8% sales growth and 4.18% return on equity
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone intraocular lenses, as well as preloaded injectors for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. STAAR Surgical Company markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, and Italy. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Earnings Per Share
As for profitability, STAAR Surgical Company has a trailing twelve months EPS of $0.31.
PE Ratio
STAAR Surgical Company has a trailing twelve months price to earnings ratio of 129.84. Meaning, the purchaser of the share is investing $129.84 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.18%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 5.2%, now sitting on 326.24M for the twelve trailing months.
Yearly Top and Bottom Value
STAAR Surgical Company’s stock is valued at $40.25 at 01:22 EST, way below its 52-week high of $58.82 and way higher than its 52-week low of $26.66.
Volume
Today’s last reported volume for STAAR Surgical Company is 53158 which is 91.45% below its average volume of 622369.
